Treating and preventing osteoporosis (bone thinning) in women who are past menopause. It is also used to reduce the risk of invasive breast cancer in certain women who are past menopause. It may also be used for other conditions as determined by your doctor. Evista is a selective estrogen receptor modulator (SERM). It works in osteoporosis by decreasing bone breakdown and thinning that may occur in women after menopause. It works to decrease the risk of invasive breast cancer by blocking estrogen in breast and uterine tissue.
Evista (raloxifene) is prescribed to postmenopausal women to prevent osteoporosis and breast cancer. The drug is part of the estrogen agonist/antagonists drug class. This class can also be referred to as a selective estrogen receptor modulator (SERM).
Evista (raloxifene) is a selective estrogen receptor modulator which works by affecting the body formation and breakdown cycle in the body thus reducing the loss of bone tissue. This medication acts like estrogen in various parts of the body.
Evista is mainly used to treat and prevent osteoporosis especially in postmenopausal women. This medication is also used to reduce the risks of breast cancer in postmenopausal women with osteoporosis. Evista helps in slowing down bone loss and making bones stronger.
However, this medication may also be used to treat other conditions as determined by the doctor. Note that Evista does not treat breast cancer. Consult your doctor for more information.